News - Tresiba

Filter

Current filters:

Tresiba

Popular Filters

Novo Nordisk’s profits rise 15% with further growth expected

Novo Nordisk’s profits rise 15% with further growth expected

30-01-2014

Danish insulin giant Novo Nordisk has announced a 15% growth in profit in the firm’s 2013 financial…

DenmarkDiabetesFinancialNovo NordiskPharmaceuticalTresibaVictoza

Novo Nordisk accused of delaying information release under Danish STC rules

Novo Nordisk accused of delaying information release under Danish STC rules

10-12-2013

Danish insulin giant Novo Nordisk revealed this morning that the Danish Financial Supervisory Authority…

DenmarkDiabetesEuropeFinancialLegalNovo NordiskPharmaceuticalRyzodegTresiba

Novo Nordisk files Tresiba/Victoza combo IDegLira for EU approval

31-05-2013

Danish insulin giant Novo Nordisk (NOV: N) said today (May 31) that it has submitted a marketing authorization…

DiabetesEuropeIDegLiraNovo NordiskPharmaceuticalRegulationTresibaVictoza

Novo Nordisk debuts Tresiba in UK and Denmark

04-03-2013

Danish insulin giant Novo Nordisk (NOVN: N) has started the European roll-out of its Tresiba (insulin…

DiabetesEuropeMarkets & MarketingNovo NordiskPharmaceuticalTresiba

Novo Nordisk now ready to launch Tresiba in Japan, following pricing accord

13-02-2013

Danish insulin giant Novo Nordisk (NOV: N) yesterday announced that it has received approval of the price…

Asia-PacificDegludecDiabetesMarkets & MarketingNovo NordiskPharmaceuticalPricingTresiba

Blow for Novo Nordisk, as FDA further delays Tresiba and Ryzodeg

11-02-2013

Danish insulin giant Novo Nordisk (NOV: N) revealed late Sunday that, on February 8, it received a Complete…

DegludecDiabetesNorth AmericaNovo NordiskPharmaceuticalRegulationRyzodegTresiba

EU approval for Novo Nordisk's Tresiba and Ryzodeg and for Novartis' for Bexsero

22-01-2013

Following positive recommendations from the European Medicines Agency's advisory committee, the European…

BexseroDiabetesEuropeNovartisNovo NordiskPharmaceuticalRegulationRyzodegTresibaVaccines

Novo Nordisk's Ryzodeg passes regulatory hurdle in Japan; diabetes burden review

03-12-2012

Global insulin market leader Novo Nordisk (NOV: N) of Denmark revealed this morning that its Ryzodeg…

Asia-PacificDegludecDiabetesGlobalHealthcareNovo NordiskPharmaceuticalPricingRegulationRyzodegTresiba

Zealand Pharma valuation hinged on Lyxi/Lanti "fixflex"

23-11-2012

The recent European Medicine Agency advisory committee, CHMP, positive opinion for French drug major…

BiotechnologyDiabetesFinancialLantusLyxumiaNovo NordiskRegulationResearchSanofiTresibaVictozaZealand Pharma

FDA accepts Merck & Co's suvorexant; panel backs Novo's Tresiba and Ryzodeg

09-11-2012

US drug giant Merck & Co (NYSE: MRK) says that the New Drug Application for suvorexant, the company's…

DegludecDiabetesMerck & CoNeurologicalNorth AmericaNovo NordiskPharmaceuticalRegulationRyzodegsuvorexantTresiba

FDA briefing papers for Novo Nordisk's insulin degludec note need to review cardiac risks

06-11-2012

The US Food and Drug Administration yesterday published the briefing documents ahead of the Advisory…

DegludecDiabetesNorth AmericaNovo NordiskPharmaceuticalRegulationRyzodegTresiba

Novo Nordisk says US FDA advisory panel to focus on degludec cardiovascular safety

26-10-2012

Denmark-based insulin giant Novo Nordisk (NOV: N) late yesterday announced that the US Food and Drug…

DegludecDiabetesNorth AmericaNovo NordiskPharmaceuticalRegulationRyzodegTresiba

EMA panel backing for Novo Nordisk's Tresiba and Ryzodeg: Japanese review

22-10-2012

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Friday announced…

Asia-PacificDegludecDiabetesEuropeNovo NordiskPharmaceuticalRegulationRyzodegTresiba

FDA further delays Novo Nordisk's ultra long-acting insulin products Tresiba and Ryzodeg

19-07-2012

Denmark's Novo Nordisk (NOV: N), the world's largest insulin maker, says that the US Food and Drug Administration…

DiabetesNorth AmericaNovo NordiskPharmaceuticalRegulationRyzodegTresiba

Novo Nordisk starts year with 15% net profits hike

30-04-2012

Danish insulin giant Novo Nordisk (NOV: N) reported first-quarter 2012 results last Friday, with a 13%…

DegludecDiabetesFinancialNovo NordiskPharmaceuticalRyzodegTresiba

Company Spotlight

Fibrotech

Fibrotech

Back to top